Company intelligence / Profile preview

Anavasi Diagnostics

Seattle / Redmond, Washington, United Statesanavasidx.com ↗

Ownership: Private
Employees: ~35
Development stage: Commercial

Overview

The company’s lead product, the AscencioDx COVID‑19 Molecular Detector and Test, delivers rapid molecular results for SARS-CoV‑2 in as little as 20–30 minutes at the point of care. It uses RT-LAMP technology to provide PCR-equivalent accuracy without centralized lab processing. The system has received FDA Emergency Use Authorization but not full approval or clearance. Clinical trials were completed within a year of founding; further expansion into additional infectious disease diagnostics using the same platform is planned.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostic test (RT-LAMP technology)
Industry: Molecular Diagnostics

Partnerships

National Institutes of Health / RADx program support/funding

Beyond the preview

Go deeper on Anavasi Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anavasi Diagnostics.

Explore the full profile